Featured in
Pipeline //
Aventera’s lead candidate is currently in the preclinical stage, advancing along a clear trajectory toward first-in-human (FIH) studies in 2028.
Science //
Severe invasive Group A Streptococcal (iGAS) infections are surging, and standard-of-care treatments are proving inadequate. Current protocols rely heavily on antibiotics; however, escalating antimicrobial resistance and stagnant clinical outcomes underscore the critical limitations of existing approaches.
0
Mortality In severe invasive infections, despite current standard of care.
0
U.S. Cases Annual incidence with a growing burden on healthcare systems.
Blockbuster Market Potential:
Independent market research confirms that addressing this rare, high-mortality indication enables a premium pricing strategy for a new clinical asset.
Rapid verification
Routine Strep-A rapid tests provide reliable, immediate identification of the bacterial target.
Aventera is bringing precision medicine to the fight against Invasive Group A Streptococcal (iGAS) infections. We have isolated potent protective antibodies from individuals who have successfully overcome severe streptococcal infections.
Aventera combines deep scientific expertise with proven experience in drug development, manufacturing, and business development.
Arman Izadi
CEO, Founder
MD/PhD, Lund University.
Clinical experience from Skåne and Karolinska University Hospitals.
Expert in Antibody Biology & Infection medicine. Inventor of core patents.
Caitriona Grönberg
Head of Preclinical
PhD, Lund University.
Former Project Manager at Cantargia, contributing to the CAN10 asset acquired in a $560M deal by Otsuka.
Expert in Inflammatory Diseases and Translational Research.
Lena Wester Rosenlöf
Head of CMC
PhD, Lund University.
Proven track record in stability design and regulatory filings for US & Europe with Hansa Biopharma and A1M Pharma.
Expert in CMC and Protein Chemistry.
Göran Forsberg
Chairman of Board of Directors
PhD, Lund University.
Successfully raised $200M in capital resulting in several clinical programs, where one was sold at $560M to Otsuka Pharmaceuticals in 2025.
Extensive Antibody Therapeutics C-level experience.
Eddie Thordarson
Board of Directors
PhD, Lund University. LU Ventures, company builder, portfolio manager.
Led the work to put a drug from preclinical phase to first in human as COO at A1M Pharma.
Extensive entrepreneurial and C-level experience.
Fredrik Joabsson
Board of Directors
PhD, Lund University.
CBDO at Camurus. Recently led and negotiated a landmark global licensing agreement with Eli Lilly in 2025, valued at $870M).
Expert in BD and investor relations. Extensive C-level Biotech Industry experience.
Liselotte Larsson
Board of Directors
PhD, Lund University.
Former COO at Cantargia; co-led the $560M deal with Otsuka Pharmaceuticals. Former Senior director of business development (BD) at Camurus.
Expert in CMC and BD. Extensive Biotech Industry C-level experience.
Pontus Nordenfelt
Chairman of the Scientific Advisory Board, Board of Directors, Founder
PhD, Lund University. Postdoc Immunology, Harvard University.
Head of Quantitative Immunobiology Group at Lund University.
Expert in GAS and Antibody Biology. Inventor of core patents.
Victor Nizet
Scientific Advisory Board
MD, Stanford University.
Distinguished Professor at USCD. Former Chief resident in Pediatrics at Harvard University / Boston Children’s Hospital. NAS-member.
Expert in GAS and Infection Biology.
Michael Dustin
Scientific Advisory Board
PhD, Harvard University.
Distinguished Professor at Oxford University. Director of the Kennedy Institute. NAS-member.
Expert in Immunology and Cancer Biology.
Adam Linder
Scientific Advisory Board
MD/PhD Infection Medicine, Lund University.
Senior Consultant in Infection Medicine at Lund University Hospital and Professor in Infection Medicine. Founder of Sepsisfonden.
Expert in severe bacterial infections, sepsis and clinical biomarkers.
Research and publications //
Streptococcus pyogenes can cause invasive disease with high mortality despite adequate antibiotic treatments. To address this unmet need, we have previously generated an opsonic IgG1 monoclonal antibody..
Group A streptococci have evolved multiple strategies to evade human antibodies, making it challenging to create effective vaccines or antibody treatments..
Antibodies play a central role in the immune defense against SARS-CoV-2. Emerging evidence has shown that nonneutralizing..
